Dicerna Pharmaceuticals Inc., of Cambridge, Mass., priced an underwritten registered public offering of 2.75 million common shares (NASDAQ:DRNA) at $17.75 apiece, expecting to raise $48.8 million, and granted underwriters a 30-day option to purchase up to 412,500 additional common shares, potentially generating another $7.3 million.